|
Q4 FY2026
As of Jun 30, 2026
|
Q4 FY2025
As of Jun 30, 2025
|
Q4 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Jun 30, 2022
|
Q4 FY2021
As of Jun 30, 2021
|
Q4 FY2020
As of Jun 30, 2020
|
Q4 FY2019
As of Jun 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|
| Non-current assets | ||||||||
| Intangible assets | ||||||||
| Property, plant and equipment | ||||||||
| Biological assets | ||||||||
| Investments in associates and joint ventures | ||||||||
| Other investments | ||||||||
| Other receivables | ||||||||
| Other financial assets | ||||||||
| Deferred tax assets | ||||||||
| Post-employment benefit assets | ||||||||
| Non-current assets | ||||||||
| Current assets | ||||||||
| Inventories | ||||||||
| Trade and other receivables | ||||||||
| Corporate tax receivables | ||||||||
| Assets held for sale | ||||||||
| Other financial assets | ||||||||
| Cash and cash equivalents | ||||||||
| Current assets | ||||||||
| Total assets | ||||||||
| Current liabilities | ||||||||
| Borrowings and bank overdrafts | ||||||||
| Other financial liabilities | ||||||||
| Share buyback liability | ||||||||
| Trade and other payables | ||||||||
| Liabilities held for sale | ||||||||
| Corporate tax payables | ||||||||
| Provisions | ||||||||
| Current liabilities | ||||||||
| Non-current liabilities | ||||||||
| Borrowings | ||||||||
| Other financial liabilities | ||||||||
| Other payables | ||||||||
| Provisions | ||||||||
| Deferred tax liabilities | ||||||||
| Post-employment benefit liabilities | ||||||||
| Non-current liabilities | ||||||||
| Total liabilities | ||||||||
| Net assets | ||||||||
| Equity | ||||||||
| Share capital | ||||||||
| Share premium | ||||||||
| Other reserves | ||||||||
| Retained earnings | ||||||||
| Equity attributable to equity shareholders of the parent company | ||||||||
| Non-controlling interests | ||||||||
| Total equity |
Loading...
